By Fineline Cube 
Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK 122.7 billion (USD 20.2 billion), driven by strong performance in GLP‑1 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.
Financial Performance Summary
| Metric | 2025 Result | YOY Growth (CER) | USD Conversion |
|---|---|---|---|
| Global Sales | DKK 309 B | +10% | USD 48.9 B |
| Operating Profit | DKK 122.7 B | +6% | USD 20.2 B |
| Diabetes & Obesity Care | DKK 289.5 B | +10% | — |
| Obesity Therapy Revenue | — | +31% | — |
| GLP‑1 Diabetes Revenue | — | +6% | — |
| Rare Disease Revenue | DKK 19.6 B | +9% | — |
Geographic Revenue Breakdown
| Region | 2025 Revenue (DKK) | YOY Growth | Key Highlights |
|---|---|---|---|
| United States | 173.2 B | +8% | 340B rebate reversal impact |
| Europe & Canada | 66.1 B | +16% | Strong growth across markets |
| Emerging Markets | 30.4 B | +8% | Stable performance |
| Asia‑Pacific | 20.7 B | +25% | High growth region |
| Greater China | 18.7 B | +5% | Weight‑loss therapy +182% |
China Market Performance
- Greater China Revenue: DKK 18.658 billion (+5% YOY)
- Weight‑Loss Therapy Sales: DKK 824 million (+182%)
- Semaglutide Sales: DKK 796 million (+314% surge)
- Strategic Value: China remains key growth driver despite overall moderate growth rate
2026 Outlook & Strategic Impact
- Operating Profit Guidance: +11% growth projected for 2026, positively impacted by USD 4.2 billion reversal of sales rebate provisions related to the US 340B Drug Pricing Program
- GLP‑1 Market Dominance: Ozempic and Wegovy continue to drive obesity and diabetes segments globally
- Portfolio Expansion: Rare disease growth of 9% demonstrates diversified revenue base
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue growth, operating profit projections, and market performance for 2026. Actual results may differ due to competitive dynamics, regulatory changes, and currency fluctuations.-Fineline Info & Tech